Pharmacologic class (EPC) · 3 drug pages

Platelet aggregation inhibitor: adverse event reports filed with FDA

4,639 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

4,639
reports across the class: 0% of all reports; 108
reports, 12 months to June 2026: 51 in the 12 months before; 87.3%
marked serious by the reporter: 57.4% across all reports; 3
drugs with a page: brand and generic names counted separately

Platelet aggregation inhibitor is a pharmacologic class (an FDA Established Pharmacologic Class) with 3 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 4,639 adverse event reports received by FDA, 0% of the database, from January 2004 to June 2026.

108 reports arrived in the 12 months to June 2026, up 112% from 51 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 87.3% of the class's reports are marked serious, 13.2% record death among the outcomes and 28.1% record hospitalisation, as reported.

Across the class the reactions recorded most often are hypotension (10.4%), cognitive disorder (10.1%) and fall (10.1%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
AggrastatTirofiban	brand	2,340	49	87.1%	Haemorrhage
Dipyridamole	generic	1,695	48	96.3%	Cognitive disorder
Eptifibatide	generic	604	11	62.4%	Myocardial infarction

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Hypotensionlow blood pressure10.4%483
Cognitive disorderproblems with thinking or memory10.1%469
Falla fall10.1%467
Depressed level of consciousness9.7%452
Painpain, site not specified9.4%434
Sedation complication9.3%433
Orthostatic hypotension9.3%430
Balance disorderproblems with balance9.2%426
Mobility decreasedreduced ability to move about9.1%421
Constipationconstipation9.1%420
Sedationdrowsiness from a medicine9.1%420
Blood calcium decreased9%416
Creatinine renal clearance decreased9%416
Haemorrhagebleeding8.7%405
Myocardial infarctionheart attack8.4%391
Toxicity to various agentspoisoning or toxic effect of one or more substances8.2%382
Thrombocytopenialow platelets6.6%305
Haemorrhage intracranial4.3%201
Angina pectoris4.1%191
Cerebral haemorrhage3.3%155
Deaththe patient died; cause not stated by this term3.3%152
Off label useused for a purpose or in a way not on the label3%139
Dyspnoeashortness of breath2.9%136
Drug interactionan interaction between medicines2.7%127
Cardiac failure acute2.5%117

Solid bar: share of all class reports. Hollow bar: the median share across the 3 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death13.2%611

Life-threatening11%511

Hospitalisation (initial or prolonged)28.1%1,305

Disability1.2%54

Congenital anomaly0%2

Other serious61.3%2,844

Not serious12.7%591

Patient age

Under 20.7%31

2 to 111.1%52

12 to 170.7%34

18 to 442.8%129

45 to 6410%463

65 to 749.3%430

75 and over17.9%831

Age not given57.5%2,669

Who reported

Physician43.9%2,035

Pharmacist5.7%263

Other health professional37.4%1,736

Lawyer0.1%3

Consumer or non-health professional5.7%263

Not given7.3%339

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Platelet aggregation inhibitor reports

Which drugs are in the Platelet aggregation inhibitor class on this site?

Aggrastat, Dipyridamole and Eptifibatide. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

4,639 reports through June 2026, 108 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

hypotension (10.4%), cognitive disorder (10.1%), fall (10.1%), depressed level of consciousness (9.7%) and pain (9.4%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.